Company
Memphasys Limited
Headquarters: Homebush, NSW, Australia
CEO: Ms. Alison Mary Coutts B.E., M.B.A., B.E. (Chem), GDipBiotech, MBA
Market Cap
A$13.6 Million
AUD as of Jan. 1, 2024
US$9.2 Million
Memphasys Limited Categories
Australia Healthcare BiotechnologyAustralia Healthcare Australia Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Memphasys Limited has the following listings and related stock indices.
Stock: ASX: MEM wb_incandescent